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Abstract : Reports on surveillance systems useful for determining the risk of 
developing hepatocellular carcinoma （HCC） after direct-acting antiviral （DAA） 
treatment for hepatitis C have been published.  Liver cirrhosis （LC） is a high-risk 
factor for HCC, but the evaluation frequency necessary for patients with chronic 
hepatitis （CH） remains unknown.  Here, we aimed to identify how frequent CH 
patients should be evaluated for HCC, with particular emphasis on patients achiev-
ing a sustained virological response （SVR） with DAA treatment.  Data were col-
lected pre-treatment （Pre） and at the time of SVR for 141 patients with hepatitis 
C receiving DAA treatment.  We dened LC by a platelet （PLT） count ≤ 10×104/
µl, and CH was dened by a PLT count of ＞ 10×104/µl.  The incidence of HCC 
in patients with CH after achieving SVR was retrospectively evaluated.  In total, 
128 patients （CH, n＝102; LC, n＝26） achieved SVR, and 13 developed HCC 
after SVR during the follow-up period （mean, 748 days）.  Although fibrosis-4 
（FIB-4） index, the presence of α -fetoprotein, and prothrombin time were signi-
cant risk factors for HCC in patients with CH in the univariate analysis, only the 
Pre-FIB-4 index was an independent predictive factor for HCC development in the 
multivariate analysis （p＝0.04）.  An FIB-4 index ≥ 3 was a signicant risk factor 
for HCC （p＝0.005）.  The cumulative risk for HCC at 1000 days was 2.6％ and 
24.2％ in the FIB-4 index ＜3 and FIB-4 index ≥ 3 groups, respectively （p＝0.004）.  
Frequent HCC examination is recommended for FIB-4 index ≥ 3 CH patients who 
obtain SVR after DAA treatment.
Key words : FIB-4 index, hepatocellular carcinoma, chronic hepatitis C, direct-acting 
antiviral, platelet count
Introduction
　Direct-acting antiviral （DAA） therapy is the first therapeutic choice for eradicating hepatitis 
C virus （HCV）, since it has been shown to enable a sustained virological response （SVR） in 
almost 100％ of the patients receiving it1-4）.  However, key issues remain, including treatment 
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failure, acquisition of antiviral resistance5, 6）, and development of HCC.  Similar to interferon 
（IFN） therapy, DAA treatment improves liver status and suppresses HCC development7-11）.  Only 
a few reports have evaluated the risk of HCC developing after DAA treatment.  In order to 
assess the risk of HCC developing after DAA therapy, α-fetoprotein （AFP）, fibrosis-4 （FIB-4） 
index, and post-treatment levels of Wisteria floribunda agglutinin-positive Mac-2 binding protein 
（WFA＋M2BP） have been considered as useful screening biomarkers7, 8, 12）.  However, the risk 
stratification still remains unclear because of the differences in inflammatory response in liver 
diseases.  As liver cirrhosis （LC） is a well-known high-risk factor of HCC even in cases where 
treatment with DAA has been successfully administered13）, estimating the incidence of HCC after 
SVR is challenging, especially in cases of a chronic liver disease that involves mild-to-moderate 
inflammation.  Because LC and chronic hepatitis （CH） are difficult to distinguish accurately 
without liver biopsy analysis, we tentatively defined LC and CH in the present study using 
platelet （PLT） counts.  Several studies have shown that a PLT count of less than 105/µl indicates 
advanced liver fibrosis and significant cirrhosis14-16） and is linked to a high incidence of HCC17-19）. 
Kang et al.  showed that a PLT count less than 105/µl was associated with a high incidence of 
underlying liver cirrhosis20）.  We classified liver status according to PLT count so that if the PLT 
count was higher than 105/µl, we considered the liver status as CH, and if the PLT count was 
lower than 105/µl, we considered it as LC.
　An HCC detection surveillance algorithm has been published for determining the frequency 
image examination for LC and CH patients21）.  However, data on improvement of liver function 
after DAA treatment was not considered.  We therefore performed a study to clarify the 
appropriate frequency of surveillance for HCC detection, with particular emphasis on patients 
with CH who successfully achieved SVR.
Methods
2.1. Study population
　In total, 141 patients with HCV-related liver disease were treated with IFN-free DAA therapy 
from October 1, 2014 through July 31, 2018 in a single-center hospital.  Among these, 131 
patients （93％） achieved “SVR-12,” which means that these patients were serologically HCV-
negative for more than 12 weeks after the treatment.  Three patients who developed HCC 
before SVR were excluded because they may have had HCC prior to beginning the DAA 
treatment.  Thus, 128 patients who had achieved SVR, including 10 patients who developed HCC 
after SVR, were included in the analysis.
　This study was performed in compliance with the Declaration of Helsinki and the Ethical 
Guidelines for Medical and Health Research Involving Human Subjects.  The Ethics Committee 
of Showa University Hospital approved the study protocol （Permit Number: 2461）.
2.2. Patient characteristics
　We collated baseline data, including data on age, sex, and HCV genotype, and extracted 
relevant laboratory test results at both pre-treatment （Pre） and post-SVR time points.  With 
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respect to PLT counts, we defined LC by a PLT count less than 105/µl and CH by more than 105/
µl.  The FIB-4 index22）, aspartate aminotransferase （AST）-to-PLT ratio index （APRI）23）, albumin-
bilirubin （ALBI） grade24）, and WFA＋M2BP, which is an M2BP glycan isomer （M2BPGi）25）, were 
used as surrogate markers of liver fibrosis and liver function.  The formulas for calculating these 
surrogate markers are shown in Figure 1.
2.3. Incident cases of HCC
　Incident cases of HCC were defined as those patients who developed HCC after having 
achieved at least SVR-12.  All patients who achieved SVR were followed at 3- to 6-month 
intervals with ultrasonography, helical dynamic computed tomography （CT）, and gadoxetate 
disodium-enhanced magnetic resonance imaging （EOB-MRI）.  The diagnosis of HCC was 
established by dynamic CT or EOB-MRI.
2.4. Statistical analysis
　The Wilcoxon rank sum test was used to evaluate the background of patients treated with 
DAA.  All p values ＜0.05 on two-tailed testing were considered significant.  The risk factors for 
HCC development after DAA treatment were evaluated using Cox proportional hazards model. 
The HCC occurrence rate was evaluated by Kaplan-Meier curves.  The cumulative incidence of 
HCC was evaluated by the log-rank test.  Statistical analysis was performed using JMPⓇ Pro 
14.0.0（SAS Institute Inc., Cary, NC, USA）.
Results
3.1. Patient characteristics
　The characteristics of the 128 patients with SVR and SVR data are shown in Table 1.  DAA 
treatment significantly reduced liver inflammation and fibrosis markers during SVR without, 
however, affecting PLT counts.  This suggests that the PLT count reflects the actual liver status 
regardless of HCV presence.  Furthermore, PLT count can be used as a proxy to differentiate 
between the liver status of patients with CH and those with LC, as shown in Table 2.  Seven 
Fig. 1.  The formulas for calculation of surrogate markers of liver fibrosis and liver 
function
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patients with CH and three patients with LC developed HCC after achieving SVR.
3.2. Risk factors associated with hepatocellular carcinoma （HCC）
　Data from pre- and post-SVR following DAA treatment were evaluated because the pre-
SVR records covered data on both the inflammatory response in the presence of HCV and 
cumulative liver damage.  In contrast, DAA treatment can induce an immediate improvement of 
Table 1.   Clinical characteristics at pre-and post-DAA treatment time points of the 128 
HCV patients achieving SVR
Male/Female （n） 59/69
Age （median） 65.6 （68）
Pre SVR p value
Platelet count （×104/µl） 16.5 （ 6.6） 17.3 （ 6.3） 0.29
Prothrombin time （％） 86.5 （10.8） 88.5 （ 9.7） 0.18
Total bilirubin （mg/dl） 0.8 （ 0.3） 0.8 （ 0.3） 0.63
AST （U/l） 50.9 （29.1） 25.2 （ 8.9） ＜ 0.001
ALT （U/l） 51.7 （41.3） 18.4 （10.2） ＜ 0.001
Albumin （g/dl） 4.1 （ 0.4） 4.2 （ 0.3） ＜ 0.002
AFP （ng/ml） 11.3 （29.1） 4.2 （ 3.2） ＜ 0.001
M2BPGi 3.0 （ 2.6） 1.4 （ 1.2） ＜ 0.001
FIB-4 index 3.72 （2.62） 2.84 （1.81） ＜ 0.01
APRI 1.43 （1.35） 0.64 （0.48） ＜ 0.001
ALBI -2.71 （0.36） -2.85 （0.29） ＜ 0.002
Data are expressed as the mean （standard deviation）.  SVR: sustained virological 
response
Table 2.   The characteristics of patients with CH and LC based on baseline PLT counts
　 CH （n＝102） LC （n＝12）
p value
PLT＞ 10×104/µl PLT ≤ 10×104/µl
Male/Female 49/53 10/16 ＜ 0.005
Age 64.9 （11.4） 68.4 （10.1） 0.21
Prothrombin time （％） 88.8 （ 9.9） 77.2 （ 9.3） ＜ 0.001
Total bilirubin （mg/dl） 0.76 （0.25） 0.99 （0.35） ＜ 0.003
AST （U/l） 48.4 （28.6） 60.4 （29.6） ＜ 0.02
ALT （U/l） 50.3 （43.2） 57.1 （32.9） 0.07
Albumin （g/dl） 4.1 （ 0.3） 3.8 （ 0.5） ＜ 0.001
AFP （ng/ml） 7.8 （21.5） 25.0 （46.7） ＜ 0.001
M2BPGi 2.24 （1.63） 5.68 （3.45） ＜ 0.001
FIB-4 index 2.76 （1.50） 7.51 （2.67） ＜ 0.001
APRI 1.02 （0.76） 3.07 （1.83） ＜ 0.001
ALBI -2.79 （0.29） -2.39 （0.43） ＜ 0.001
Data are expressed as the mean （standard deviation）.
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inflammation at the time of SVR26）.  The SVR point may reflect true accumulated liver damage. 
Multivariate analyses were performed for data obtained pre-treatment and post-SVR points, 
taking into consideration fibrosis parameters such as FIB-4 index, APRI, and ALBI grade.  At 
the pre-treatment point, prothrombin time （PT）％, AFP, and FIB-4 index significantly deferred 
between the non-HCC and HCC groups in the univariate analysis, and only the FIB-4 index 
was an independent predictor of HCC in the multivariate analysis （p＝0.04） （Table 3）.  At 
the time of SVR, PT％, AST, AFP, and FIB-4 index were identified as parameters predictive of 
HCC incidence by univariate analysis.  Although there were no significant differences, the FIB-












Age 64.4 （11.4） 72.1 （ 8.4）
Prothrombin time （％） 89.6 （ 9.6） 80 （ 8.8） 0.01 0.05
Total bilirubin （mg/dl） 0.75 （0.25） 0.86 （0.31）
AST （U/l） 48.4 （29.4） 48.4 （13.8）
ALT （U/l） 50.9 （44.4） 42.1 （20.6）
Albumin （g/dl） 4.1 （ 0.3） 3.9 （ 0.3）
AFP （ng/ml） 7.6 （22.2） 11 （ 5.9） 0.004 0.89
M2BPGi 2.21 （1.59） 2.71 （2.45）
FIB-4 index 2.68 （1.51） 3.77 （0.80） 0.009 0.04
APRI 1.01 （0.78） 1.10 （0.38）
ALBI -2.81 （0.29） -2.60 （0.29）
Data are expressed as the mean （standard deviation）.











Prothrombin time （％） 90.5 （11.2） 83.3 （11.4） 0.04 0.45
Total bilirubin （mg/dl） 0.74 （0.28） 0.89 （0.25）
AST （U/l） 24.6 （ 9.3） 27 （ 3.7） 0.04 0.64
ALT （U/l） 18.0 （11.0） 16.4 （ 6.3）
Albumin （g/dl） 4.3 （ 0.3） 4.1 （ 0.4）
AFP （ng/ml） 3.9 （ 3.6） 5.7 （ 2.2） 0.009 0.35
M2BPGi 0.95 （0.44） 2.26 （1.42）
FIB-4 index 2.23 （1.27） 3.12 （0.66） 0.006 0.05
APRI 0.49 （0.26） 0.57 （0.20）
ALBI -2.91 （0.26） -2.71 （0.28） 　 　
Data are expressed as the mean （standard deviation）.
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4 index tended to be an independent predictor of HCC in the multivariate analysis （p＝0.05） 
（Table 4）.  The receiver operating characteristic （ROC） curve for the FIB-4 index at the pre-
treatment point is shown in Figure 2.  The area under the ROC curve was 0.799.  Based on 
this result, a FIB-4 index of 3 was defined as the optimum cut-off value.  Moreover, a FIB-4 
index ≥ 3 was significantly associated with a high risk of developing HCC （hazard ratio ［HR］＝
11.7; 95％ confidence interval ［CI］, 2.0-220.2; p＝0.0046）.  In addition, the cumulative risk for 
HCC at 1,000 days was 2.6％ in the FIB-4 index ＜ 3 group compared with 24.2％ in the FIB-4 
index ≥ 3 group, and the cumulative HCC incidence was significantly higher in the FIB-4 index 
≥ 3 group than that in the FIB-4 index ＜ 3 group on the log-rank test （p＝0.004） （Figure 3）.
Fig. 2.  The ROC curve for the pre-treatment fibrosis-4 （FIB-4） index
Fig. 3.  Cumulative incidence （％） of HCC in patients with CH who 
achieved a sustained virological response after DAA treatment 
compared with the pre-treatment fibrosis-4 （FIB-4） index. 
The cumulative incidence increased significantly in patients 
with CH and a FIB-4 index ≥ 3 （p＝0.004, log-rank test）.
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Discussion
　IFN-free DAA treatment can lead to HCV clearance in almost 100％ of treated cases without 
severe complications.  Although viral clearance is serologically achieved, it should be kept in 
mind that HCC could subsequently develop, despite the fact that patients with SVR have a 
reduced risk of HCC9, 10）.  In the present study, we evaluated the risk of developing HCC after 
IFN-free DAA treatment.  Generally, liver fibrosis is a high-risk factor for HCC; hence, intensive 
follow-up for patients with LC is necessary even if SVR has been achieved.  Moreover, not 
every patient with CH undergoes close imaging examination because the accumulated liver injury 
and fibrosis tend to differ from case to case.  According to scientific literature, there are factors 
that can be used to predict HCC development, such as WFA＋M2BP, FIB-4 index, AFP, and 
ALBI7, 8, 27）.  However, inflammatory responses in liver diseases are diverse and risk stratification 
is still unclear.  For this reason, this study evaluated the risk of HCC development in patients 
with CH, and we identified the risk factors for HCC.  However, it is challenging to evaluate 
the extent of liver inflammation and fibrosis in patients with CH and LC in the absence of 
data from liver biopsy analysis.  Liver biopsy is an invasive procedure, which may result in 
complications, such as pain, hemorrhage, and even mortality28）.  For these reasons, liver biopsy is 
not commonly performed in this group of patients, particularly not in those who have received 
DAA treatment.  Patients receiving DAA exhibit higher SVR rates and lower adverse reaction 
rates compared with those receiving IFN therapy.
　Here, we used PLT counts to differentiate between CH and LC.  Our data support the use 
of PLT counts to delimit the extent of liver pathology, by linking the values with CH and LC 
groups; moreover, DAA treatment did not affect the PLT count.
　In the CH group, PT％, AFP, and FIB-4 index as measured pre-treatment and at the time 
of SVR were risk factors for HCC, but only the pre-treatment FIB-4 index was identified as 
an independent risk factor of HCC by multivariate analysis.  Moreover, in the log-rank test, an 
FIB-4 index ≥ 3 was predictive of HCC.  These results suggest that classifying liver status based 
on PLT count and stratifying the risk of HCC incidence using the FIB-4 index enables feasible 
and convenient CH follow-up for surveillance of HCC developing after DAA therapy.  The 
follow-up time interval after DAA therapy would be decided by the physicians based on their 
respective experience.  In general, patients with CH would not need to undergo surveillance for 
HCC every two to three months, which is recommendable for LC patients.  However, even CH 
patients should have a periodical inspection for HCC.  The question remains, however, as to how 
often and which marker is most efficient.  We believe that our study has provided suggestions 
for appropriate markers and follow-up periods relevant to HCC surveillance after DAA therapy. 
In other words, HCV patients before DAA treatment with a PLT count ＞ 105/µl and an FIB-4 
index ≥ 3 are at a high risk of developing HCC and should be monitored frequently.
　The present study has some limitations.  The sample size analyzed was small, and the 
observation period was relatively short.  Nevertheless, our approach is considered non-invasive, 
simple, and useful for the stratification of CH and LC patients when assessing the risk of HCC 
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onset.  More evaluations are necessary with more cases for longer observation periods.
Conclusion
　A FIB-4 index ≥3 in CH patients who have obtained SVR after DAA treatment are 
considered to be at high risk of developing HCC, and frequent surveillance is recommended.
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